Pfizer Inc. and the company’s partner BioNTech SE said on April 26 that they had submitted an application to the U.S. health regulator for the authorization of a booster dose of their COVID-19 vaccine for children aged 5 to 11 years.
AstraZeneca’s Phase III Provent trial results showed a statistically significant 77 percent decrease in a patient’s likelihood of developing symptomatic COVID-19 when proactively treated with Evusheld. Additionally, results were announced by Clover Biopharmaceuticals for the Phase II/III Spectra global study investigating the efficacy of the SCB-2019 (CpG 1018/Alum) vaccine booster in patients that have previously developed a COVID-19 infection.
ReutersModerna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of the company’s COVID-19 vaccine among kids between the ages of six months to five years by the end of the month, a company spokesperson said.
Arcturus Therapeutics announced positive Phase III trial results for the company’s mRNA vaccine candidate ARCT-154, which is intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
Moderna Inc. on April 19 said a COVID-19 booster designed to target the Beta variant as well as the original coronavirus generated a better immune response against a number of virus variants including Omicron.
A fourth dose of the COVID-19 vaccine from Pfizer and BioNTech provided significant added protection against severe disease, hospitalization and death for at least a month in older individuals, according to a study from Israel conducted when the Omicron variant was dominant. Additionally, new findings suggest patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward.
A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
ReutersTop U.S. Food and Drug Administration officials on April 6 said the agency is aiming to decide by June whether to change the design of COVID-19 vaccines in order to combat future variants, even if it does not have all the necessary information to measure their effectiveness.
ReutersCurrent COVID-19 vaccines are not well-matched against the BA.2 sub-variant of Omicron, the U.S. Food and Drug Administration said on April 6, as its panel of outside experts meets to discuss changes to future booster doses.
A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study in Israel found.
